Salar Antonio, Casao Dolors, Cervera Marta, Pedro Carmen, Calafell Montserrat, Abella Eugenia, Alvarez-Larrán Alberto, Besses Carlos
Department of Clinical Hematology, Hospital del Mar, Barcelona, Spain.
Eur J Haematol. 2006 Oct;77(4):338-40. doi: 10.1111/j.1600-0609.2006.00713.x. Epub 2006 Jul 19.
We assessed the feasibility of a rapid infusion of rituximab with or without steroid-containing chemotherapy.
previous infusion of rituximab without grade 3 or 4 toxicity, lymphoid cells <5 x 10(9)/L and rituximab dose of 375 mg/m(2). Seventy patients were treated with a total of 319 rapid rituximab infusions [126 (40%) with and 193 (60%) without steroids]. Overall, rapid infusion of rituximab was well tolerated - there were no grade 3 or 4 adverse events. Only, three patients developed symptoms, all grade 1. In conclusion, rituximab administration in a 90-min infusion schedule is well tolerated and safe, both in patients who are administered steroids and in patients who are not.
我们评估了快速输注利妥昔单抗联合或不联合含类固醇化疗的可行性。
既往输注利妥昔单抗无3级或4级毒性，淋巴细胞<5×10⁹/L且利妥昔单抗剂量为375mg/m²。70例患者共接受了319次利妥昔单抗快速输注[126次（40%）联合类固醇，193次（60%）不联合类固醇]。总体而言，利妥昔单抗快速输注耐受性良好——无3级或4级不良事件。仅3例患者出现症状，均为1级。总之，无论是接受类固醇治疗的患者还是未接受类固醇治疗的患者，90分钟输注方案的利妥昔单抗给药耐受性良好且安全。
